Shares of Vanda Pharmaceuticals fell by approximately 17% in extended trading following the October 14, 2026 announcement of the VQW-765 trial failure

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

In 2022, mental health inpatient Sophie Alderman died after mistakenly believing that the Oxevision camera monitoring system would alert hospital staff to save her.

The proposed FY26 budget restructuring includes a $1 billion funding reduction affecting community mental health centers, suicide prevention, and substance use treatment programs.

The President's FY26 budget proposed dissolving the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to consolidate them into a new Administration for a Healthy America.

The Substance Abuse and Mental Health Services Administration reinstated $2 billion in mental health and substance use grants on January 14, 2026, following bipartisan pushback.

On January 13, 2026, the Substance Abuse and Mental Health Services Administration terminated hundreds of grants totaling approximately $2 billion for mental health and substance use disorder services.

Proposed FY26 restructuring threatens Health Resources and Services Administration programs that support mental health professional training and health delivery in underserved communities.

On May 12, 2025, the federal administration announced it would not enforce September 2024 Biden-era mental health parity regulations for insurance providers.

The ERISA Industry Committee legally challenged the September 2024 mental health parity rules, claiming the regulations overstepped administrative authority and raised costs.

More young people need to get their brain scanned

In England, estimated financial costs from adverse childhood experiences were £37.8 billion for mental illness and £22.7 billion for smoking, while in Wales each accounted for £1.8 billion.

Researchers observed that co-existing mental health conditions like depression, along with emotional regulation and impulse control challenges, may contribute to elevated suicide rates among people with ADHD.

A study of U.S. health data published in Lancet Psychiatry reported that GLP-1 users with schizophrenia and type 2 diabetes were less likely to be admitted to a psychiatric hospital than patients taking other types of diabetes medication

A study of U.S. health records published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who were prescribed GLP-1 receptor agonists had a 24% lower risk of psychiatric hospital admission than those not taking GLP-1s

Patients with schizophrenia and type 2 diabetes prescribed GLP-1 receptor agonists were 29% less likely to visit an emergency department for a mental health crisis compared to those not taking GLP-1s, according to a Lancet Psychiatry study

The authors of the Lancet Psychiatry study published in October 2026 emphasized that randomized controlled trials are required to confirm whether GLP-1 receptor agonists directly reduce psychiatric acute care needs in patients with schizophrenia

Study authors advised that GLP-1 receptor agonists should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric hospital admissions based on current evidence

The UK Medicines and Healthcare products Regulatory Agency announced updated safety warnings for all 28 authorised antidepressants, introducing boxed warnings on suicidal thoughts and behaviours in patient information leaflets

The Commission on Human Medicines review into antidepressant safety was initiated after patients and families raised concerns regarding the communication of suicidal thoughts and persistent sexual dysfunction risks

The Medicines and Healthcare products Regulatory Agency advised healthcare professionals to discuss suicidal risks when starting antidepressants, changing dosages, or conducting routine reviews